Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: M05BA06

Ibandronic Acid Hexal(ibandronic acid)

Hypercalcemia;Breast Neoplasms;Osteoporosis;Neoplasm Metastasis

Marketing Authorisation Holder: Hexal AG

INN: ibandronic acid

Indication

Ibandronic Acid Hexal is indicated for Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. Treatment of tumour-induced hypercalcaemia with or without metastases.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ibandronic Acid Hexal — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.